Top Story Today
Sanofi Broke Up With the FDA's Fast-Track Program Over Political Meddling
Sanofi asked the FDA to pull its diabetes drug Tzield from the agency's brand-new Commissioner's National Priority Voucher program, which promises decisions in one to two months instead of the usual 10-12. The reason: a political appointee, Tracy Beth Hoeg, reportedly opposed career scientists who recommended the fast-track review proceed. Across 1,000+ patients studied over 30 years, the safety concerns she cited (cancer risk) amounted to 3 cases with no established causal link. It's extremely rare for a center director to override individual scientific reviews, and even rarer when that director is a political appointee rather than a career regulator.
Why it matters: If political appointees can veto career scientists on individual drug decisions, every company in the FDA pipeline has to wonder whether their review will be decided by data or by someone's agenda. The CNPV program's first major test case ended with the applicant walking away, and that credibility problem won't be easy to fix.
Read more →Clinical & Regulatory
The FDA Just Started Streaming Clinical Trial Data Like Netflix
Amgen and AstraZeneca are now feeding live clinical trial data to FDA reviewers through a cloud platform, ditching the 60-year-old model of running a study, packaging results, and mailing everything over. The pilot could compress development timelines by months, letting regulators greenlight phase transitions without waiting for final submissions. The FDA plans a broader rollout this summer.
Read more →The FDA Reversed Its Own Rejection of a Rare Cancer Therapy
Three months after rejecting Ebvallo (a cell therapy for a rare, often fatal post-transplant cancer), the FDA agreed to reconsider, saying the existing trial data is sufficient for review after all. No new data was generated. Internal reviewers had originally recommended approval before leadership overruled them. The reversal follows intense pressure from patient advocates and bipartisan lawmakers.
Read more →Congress Wants to Ban Monkey Imports, and Drug Developers Are Watching
A bipartisan bill would prohibit importing nonhuman primates into the U.S., threatening the 20,000+ macaques shipped annually for preclinical drug testing. Domestic breeding can't fill the gap quickly, and primate studies remain required for most biologics. The FDA is already nudging companies toward alternatives like organoids and AI models, but validation timelines remain uncertain.
Read more →Deals & M&A
UCB Paid $2.2 Billion for a Company That Barely Existed
UCB acquired Candid Therapeutics, a biotech that launched from stealth just 18 months ago, for $2.0 billion upfront plus milestones. The target: bispecific T-cell engagers that could deliver CAR-T-like immune resets for autoimmune diseases as a simple injection. Candid's founder previously sold RayzeBio to Bristol Myers Squibb for $4.1 billion. His combined exit total now sits at $6.3 billion.
Read more →Ipsen Quietly Trashed Two Drugs From Its $952M Acquisition
Two pipeline candidates from Ipsen's 2023 Albireo Pharma acquisition have been shelved after one trial couldn't recruit enough patients and the other never advanced past early development. The crown jewel, Bylvay, is thriving with 100%+ segment growth. But the pattern is familiar: pharma pays premium prices for a lead asset and quietly discards the extras.
Read more →Funding & Pipeline
A Tiny Biotech Just Embarrassed AbbVie in Skin Disease
Avalo Therapeutics posted Phase 2 results in hidradenitis suppurativa showing 42-43% response rates, beating AbbVie's own candidate on absolute efficacy. Shares spiked 45%, and the company raised $375 million overnight to fund Phase 3. Analysts slapped a consensus "Strong Buy" on the stock with price targets implying 200%+ upside. The acquisition chatter has already started.
Read more →One Serious Adverse Event Killed a $70M Biotech Overnight
Tempero Bio paused its Phase 2 alcohol use disorder trial and is evaluating options for the program. The company raised $70 million barely a year ago for a brain-targeted drug that showed promise in Phase 1. Management declined to reveal what drove the decision, leaving other companies working on similar glutamate-related targets without critical information.
Read more →$83M Bet on the Immune System's Overlooked Fighters
London-based Cytospire raised an oversubscribed $83 million Series A to develop T-cell engagers that recruit gamma delta T cells (tissue-resident immune cells that make up just 1-5% of circulating T cells). The approach sidesteps the exhaustion and manufacturing problems plaguing conventional T-cell therapies in solid cancers.
Read more →